Pharmacology  ·  Antibacterial Agents

Metronidazole, Clindamycin & Miscellaneous Agents

Anaerobic coverage, toxin suppression, urinary tract agents, and last-resort polymyxins

Abbreviations: TMP-SMX = trimethoprim-sulfamethoxazole  ·  MRSA = methicillin-resistant Staphylococcus aureus  ·  CA-MRSA = community-acquired MRSA  ·  MLSB = macrolide-lincosamide-streptogramin B  ·  UTI = urinary tract infection  ·  PCP = Pneumocystis jirovecii pneumonia  ·  ESBL = extended-spectrum beta-lactamase  ·  CRE = carbapenem-resistant Enterobacteriaceae  ·  DHPS = dihydropteroate synthase  ·  DHFR = dihydrofolate reductase  ·  LPS = lipopolysaccharide

Metronidazole
Mechanism and Spectrum
Metronidazole

Mechanism

  • Reductive activation by anaerobic ferredoxin enzymes → nitro radical anion → DNA strand breaks
  • Bactericidal; inactive in aerobic organisms (wrong redox potential for activation)
  • Excellent oral bioavailability; good CNS and tissue penetration

Spectrum

  • All major anaerobes: B. fragilis, C. perfringens, Fusobacterium, oral anaerobes
  • C. difficile: previously first-line; now replaced by oral vancomycin or fidaxomicin per 2017 IDSA/SHEA guidelines
  • Protozoa: Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica
  • No aerobic antibacterial activity
Adverse Effects and Drug Interactions
Key Toxicities

Disulfiram-Like Reaction

  • Inhibits aldehyde dehydrogenase → acetaldehyde accumulates with alcohol
  • Avoid all alcohol during therapy and for 48 hours after completion

Neurological (Prolonged Use)

  • Peripheral neuropathy — may be irreversible; discontinue if symptoms develop
  • CNS toxicity: ataxia, encephalopathy — characteristic reversible MRI signal changes in cerebellar dentate nuclei and corpus callosum

Drug Interactions

  • Inhibits CYP2C9 → ↑ warfarin effect — monitor INR closely
  • Reduces renal lithium clearance → lithium toxicity risk
Clindamycin
Mechanism, Spectrum, and Pharmacokinetics
Clindamycin

Mechanism

  • Binds 50S ribosomal subunit at peptidyl transferase center → bacteriostatic
  • Suppresses toxin production at sub-inhibitory concentrations — add to beta-lactam for necrotizing fasciitis, streptococcal toxic shock syndrome, and staphylococcal toxic shock syndrome

Spectrum

  • CA-MRSA skin/soft tissue (confirm D-zone negative); MSSA; streptococci
  • Most gram-positive anaerobes; many B. fragilis (resistance increasing)
  • No gram-negative aerobic activity; C. difficile intrinsically resistant — clindamycin is among the highest-risk antibiotics for C. difficile colitis

Pharmacokinetics

  • ~90% oral bioavailability; excellent bone, joint, and soft tissue penetration
  • Poor CNS penetration — not for CNS infections
Adverse Effects and MLSB Resistance
Key Risks

C. difficile Colitis

  • Among highest-risk antibiotics for C. difficile — evaluate any diarrhea during or weeks after therapy
  • GI effects (diarrhea, nausea) common even without C. difficile

MLSB Resistance

  • Constitutive erm expression: high-level resistance — clindamycin reports resistant in vitro
  • Inducible erm expression: appears susceptible in vitro but erm is induced in vivo → treatment failure; detected by D-zone test
  • D-zone positive (blunted clindamycin inhibition zone adjacent to erythromycin disk) → do NOT use clindamycin
Miscellaneous Agents
Agent Mechanism Key Indications Key Adverse Effects Caution
Fosfomycin Inhibits MurA — blocks first step of peptidoglycan synthesis; covalent inactivation of the enzyme Uncomplicated cystitis (E. coli, E. faecalis); active vs. many ESBL-producing strains; single-dose oral Generally well tolerated; GI disturbance mild UTI only — insufficient systemic tissue levels; not for pyelonephritis or systemic infections
Nitrofurantoin Reductive activation → reactive intermediates damage DNA, RNA, ribosomes, and cell wall — multi-target; bactericidal in urine Uncomplicated cystitis only; active vs. most E. coli including ESBL strains; prophylaxis for recurrent UTI Pulmonary toxicity (acute hypersensitivity or chronic fibrosis with prolonged use); hepatotoxicity (rare); peripheral neuropathy Never for pyelonephritis (inadequate tissue levels); avoid if CrCl <30 mL/min (reduced urinary levels + accumulation of toxic metabolites)
TMP-SMX Sequential block: sulfonamide inhibits DHPS → trimethoprim inhibits DHFR → folate synthesis arrested at two steps UTI; CA-MRSA skin/soft tissue; PCP prophylaxis and treatment; Nocardia; Toxoplasma prophylaxis Hypersensitivity rash (sulfonamide); Stevens-Johnson syndrome; hyperkalemia (blocks renal K⁺ secretion); ↑ creatinine (blocks tubular secretion); myelosuppression (folate depletion) Sulfonamide allergy contraindication; avoid in severe renal impairment; monitor potassium and creatinine
Polymyxins Polycationic lipopeptides bind LPS on gram-negative outer membrane → membrane disruption and permeabilization → rapid bactericidal killing Carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, CRE — when no alternatives exist Nephrotoxicity (major, dose-dependent, often severe); neurotoxicity (paresthesias, neuromuscular blockade); colistin is a prodrug (colistimethate sodium) with complex PK Last-resort only — never empiric; never for organisms with available alternatives; combination therapy preferred to reduce resistance emergence

Critical Rules: C. difficile, Nitrofurantoin Scope, and Polymyxin Stewardship

Metronidazole is no longer first-line for C. difficile infection. The 2017 IDSA/SHEA guidelines recommend oral vancomycin or fidaxomicin for all initial episodes; metronidazole is reserved only when vancomycin and fidaxomicin are unavailable. This change reflects clinical trial data showing higher cure rates and lower recurrence with vancomycin.

Nitrofurantoin is strictly a lower urinary tract agent. It achieves therapeutic concentrations in urine but not in renal parenchyma, blood, or other tissues. Never prescribe for pyelonephritis, urosepsis, or any infection requiring systemic drug levels. It is also contraindicated when CrCl is below 30 mL/min — both because urinary levels become insufficient and because toxic metabolites accumulate.

Polymyxins should be considered a last resort, not part of any empiric regimen. The nephrotoxicity is often severe and not reliably reversible. When polymyxins are required, combination with another agent (typically a carbapenem or rifampin) is preferred over monotherapy to reduce resistance emergence and potentially improve outcomes.

Suggested References

Author / Source Title Publication
Katzung BG, ed. Basic and Clinical Pharmacology, 15th ed. — Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, and Oxazolidinones McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 51: Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents McGraw-Hill, 2023
Leitsch D A review on metronidazole: an old warhorse in antimicrobial chemotherapy Parasitology. 2019;146(9):1167–1178
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis. 2010;50(2):133–164
Lamp KC, Freeman CD, Klutman NE, Lacy MK Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials Clin Pharmacokinet. 1999;36(5):353–373
O'Reilly RA The stereoselective interaction of warfarin and metronidazole in man N Engl J Med. 1976;295(7):354–357
Kuriyama A, Jackson JL, Doi A, Kamiya T Metronidazole-induced central nervous system toxicity: a systematic review Clin Neuropharmacol. 2011;34(6):241–247
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America Clin Infect Dis. 2014;59(2):e10–e52
Falagas ME, Gorbach SL Clindamycin and metronidazole Med Clin North Am. 1995;79(4):845–867
Kelly CP, LaMont JT Clostridium difficile — more difficult than ever N Engl J Med. 2008;359(18):1932–1940
Leclercq R Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications Clin Infect Dis. 2002;34(4):482–492
Falagas ME, Kasiakou SK, Saravolatz LD Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections Clin Infect Dis. 2005;40(9):1333–1341
Cunha BA Nitrofurantoin — current concepts Urology. 1988;32(1):67–71
Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited Arch Intern Med. 2003;163(4):402–410
Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system Clin Infect Dis. 2011;53(9):879–884
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women Clin Infect Dis. 2011;52(5):e103–e120
McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clin Infect Dis. 2018;66(7):e1–e48